MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: a comprehensive analysis based on microarray data

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer is divided mainly into lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD), and large cell carcinoma (LCC) [1]. Although great progress has been made in targeted treatment and immunotherapy, Platinum-based combination chemotherapy is still the standard chemotherapy treatment for wild type lung adenocarcinoma, and cisplatin (DDP) is widely used [2,3].

Source: Lung Cancer - June 15, 2020 Category: Cancer & Oncology Authors: Lu Min, Hu Chunhong, Wu Fang, Shu Long, Pan Yue, Liu Xianling, Liu Ping, Fang Ma, Deng Chao, Huang Ming Source Type: research